GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pfizer Inc (CHIX:PFEd) » Definitions » EV-to-EBITDA
中文

Pfizer (CHIX:PFED) EV-to-EBITDA : 21.84 (As of Apr. 24, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Pfizer EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Pfizer's enterprise value is €194,482 Mil. Pfizer's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was €8,905 Mil. Therefore, Pfizer's EV-to-EBITDA for today is 21.84.

The historical rank and industry rank for Pfizer's EV-to-EBITDA or its related term are showing as below:

CHIX:PFEd' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.82   Med: 12   Max: 59.08
Current: 21.68

During the past 13 years, the highest EV-to-EBITDA of Pfizer was 59.08. The lowest was 5.82. And the median was 12.00.

CHIX:PFEd's EV-to-EBITDA is ranked worse than
70.76% of 708 companies
in the Drug Manufacturers industry
Industry Median: 13.88 vs CHIX:PFEd: 21.68

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-24), Pfizer's stock price is €24.56. Pfizer's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €0.340. Therefore, Pfizer's PE Ratio for today is 72.24.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Pfizer EV-to-EBITDA Historical Data

The historical data trend for Pfizer's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pfizer EV-to-EBITDA Chart

Pfizer Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.24 17.43 10.98 7.32 23.12

Pfizer Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.32 6.37 7.60 11.25 23.12

Competitive Comparison of Pfizer's EV-to-EBITDA

For the Drug Manufacturers - General subindustry, Pfizer's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pfizer's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pfizer's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Pfizer's EV-to-EBITDA falls into.



Pfizer EV-to-EBITDA Calculation

Pfizer's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=194481.791/8905.204
=21.84

Pfizer's current Enterprise Value is €194,482 Mil.
Pfizer's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €8,905 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pfizer  (CHIX:PFEd) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Pfizer's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=24.56/0.340
=72.24

Pfizer's share price for today is €24.56.
Pfizer's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.340.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Pfizer EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Pfizer's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Pfizer (CHIX:PFED) Business Description

Address
66 Hudson Boulevard East, New York, NY, USA, 10001-2192
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.

Pfizer (CHIX:PFED) Headlines

No Headlines